{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:03:35Z","timestamp":1789556615477,"version":"build-2803163510"},"reference-count":75,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Dopamine transporter (DAT) imaging is widely used to determine whether parkinsonian symptoms reflect presynaptic nigrostriatal degeneration. Although most examinations can be confidently classified as normal or abnormal, a clinically important subset remains equivocal. Such scans may show subtle posterior putaminal reduction, mild asymmetry, preserved comma-shaped morphology despite low quantitative values, or disagreement between visual and semiquantitative assessments. These findings may result from early neurodegeneration, physiological variation, medication effects, structural lesions, technical artifacts, or limitations of image processing and normative databases. This narrative review examines visual criteria, the complementary role and limitations of quantification, longitudinal outcomes of scans without evidence of dopaminergic deficit (SWEDD), common interpretive pitfalls, and the roles of clinical follow-up and repeat imaging. No universal quantitative cutoff can be applied across scanners, reconstruction methods, tracers, and software platforms. Expert visual interpretation remains the primary basis for assessment, while age- and platform-matched quantification is most useful as an adjunct in borderline cases. Integrating image quality, regional uptake pattern, quantitative findings, structural imaging, medication history, and clinical evolution may reduce diagnostic error and premature labeling of neurodegenerative parkinsonism.<\/jats:p>","DOI":"10.3390\/life16091545","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:09:17Z","timestamp":1789553357000},"page":"1545","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Equivocal Dopamine Transporter Imaging: Integrating Visual Assessment, Quantification, and Clinical Follow-Up"],"prefix":"10.3390","volume":"16","author":[{"given":"So Young","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, 110 Deokan-ro, Gwangmyeong 14353, Gyeonggi-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","article-title":"Challenges in the diagnosis of Parkinson\u2019s disease","volume":"20","author":"Tolosa","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1136\/jnnp-2012-304436","article-title":"Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with 123I-ioflupane in diagnosis of parkinsonian syndromes","volume":"84","author":"Bajaj","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13550-015-0087-1","article-title":"The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson\u2019s disease or clinically uncertain parkinsonism: A systematic review","volume":"5","author":"Suwijn","year":"2015","journal-title":"EJNMMI Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1007\/s00259-020-04817-8","article-title":"EANM practice guideline\/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0","volume":"47","author":"Morbelli","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00259-009-1267-x","article-title":"EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2","volume":"37","author":"Darcourt","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s13139-024-00840-x","article-title":"Imaging procedure and clinical studies of [18F]FP-CIT PET","volume":"58","author":"Sung","year":"2024","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3906\/sag-2008-253","article-title":"Dopamine transporter SPECT imaging in Parkinson\u2019s disease and parkinsonian disorders","volume":"51","author":"Akdemir","year":"2021","journal-title":"Turk. J. Med. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/jnnp.62.2.133","article-title":"[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson\u2019s disease","volume":"62","author":"Booij","year":"1997","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/1531-8257(200005)15:3<503::AID-MDS1013>3.0.CO;2-V","article-title":"Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: The [123I]-FP-CIT study group","volume":"15","author":"Benamer","year":"2000","journal-title":"Mov. Disord."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.3390\/clinpract13060128","article-title":"Neuroimaging techniques in differentiating Parkinson\u2019s disease from drug-induced parkinsonism: A comprehensive review","volume":"13","author":"Caprara","year":"2023","journal-title":"Clin. Pract."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00259-006-0155-x","article-title":"Quantification of [123I]FP-CIT SPECT brain images: An accurate technique for measurement of the specific binding ratio","volume":"33","author":"Hoffmann","year":"2006","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00259-012-2304-8","article-title":"Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: Results from the ENC-DAT database","volume":"40","author":"Nobili","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00259-012-2276-8","article-title":"European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): Age-related effects, gender differences and evaluation of different methods of analysis","volume":"40","author":"Varrone","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"15069","DOI":"10.1038\/s41598-023-42135-9","article-title":"Diagnostic accuracy of 18F-FP-CIT PET for clinically uncertain Parkinsonian syndrome","volume":"13","author":"Oh","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13550-018-0450-0","article-title":"Dopamine transporter imaging with [18F]FE-PE2I PET and [123I]FP-CIT SPECT\u2014A clinical comparison","volume":"8","author":"Axelsson","year":"2018","journal-title":"EJNMMI Res."},{"key":"ref_17","first-page":"1109","article-title":"Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies","volume":"46","author":"Koch","year":"2005","journal-title":"J. Nucl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00259-009-1212-z","article-title":"The impact of reconstruction method on the quantification of DaTSCAN images","volume":"37","author":"Dickson","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","article-title":"Ageing and Parkinson\u2019s disease: Substantia nigra regional selectivity","volume":"114","author":"Fearnley","year":"1991","journal-title":"Brain"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ana.21995","article-title":"Clinical progression in Parkinson disease and the neurobiology of axons","volume":"67","author":"Cheng","year":"2010","journal-title":"Ann. Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1093\/brain\/awt192","article-title":"Disease duration and the integrity of the nigrostriatal system in Parkinson\u2019s disease","volume":"136","author":"Kordower","year":"2013","journal-title":"Brain"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.neurobiolaging.2017.05.006","article-title":"Reduced dopamine receptors and transporters but not synthesis capacity in normal aging adults: A meta-analysis","volume":"57","author":"Karrer","year":"2017","journal-title":"Neurobiol. Aging"},{"key":"ref_23","first-page":"554","article-title":"Dopamine transporters decrease with age","volume":"37","author":"Volkow","year":"1996","journal-title":"J. Nucl. Med."},{"key":"ref_24","first-page":"1175","article-title":"Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CIT SPECT","volume":"36","author":"Seibyl","year":"1995","journal-title":"J. Nucl. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00259-020-05085-2","article-title":"Impact of age and sex correction on the diagnostic performance of dopamine transporter SPECT","volume":"48","author":"Lange","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s12149-017-1168-1","article-title":"Age-related effects and gender differences in Japanese healthy controls for [123I]FP-CIT SPECT","volume":"31","author":"Yamamoto","year":"2017","journal-title":"Ann. Nucl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s002590000279","article-title":"Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers","volume":"27","author":"Lavalaye","year":"2000","journal-title":"Eur. J. Nucl. Med."},{"key":"ref_28","first-page":"354","article-title":"Accurate automated quantification of dopamine transporter PET without MRI using deep learning-based spatial normalization","volume":"58","author":"Kang","year":"2024","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1474-4422(07)70057-1","article-title":"Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: A phase III, multicentre study","volume":"6","author":"McKeith","year":"2007","journal-title":"Lancet Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"w14621","DOI":"10.4414\/smw.2018.14621","article-title":"The role of molecular imaging in assessing degenerative parkinsonism\u2014An updated review","volume":"148","author":"Nicastro","year":"2018","journal-title":"Swiss Med. Wkly."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1002\/mds.21685","article-title":"Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs)","volume":"22","author":"Schneider","year":"2007","journal-title":"Mov. Disord."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/mds.21062","article-title":"123I-Ioflupane SPECT in the diagnosis of suspected psychogenic Parkinsonism","volume":"21","author":"Gaig","year":"2006","journal-title":"Mov. Disord."},{"key":"ref_33","first-page":"1688","article-title":"123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism","volume":"45","author":"Lorberboym","year":"2004","journal-title":"J. Nucl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/mds.21479","article-title":"[123I]FP-CIT spect study in vascular parkinsonism and Parkinson\u2019s disease","volume":"22","author":"Zijlmans","year":"2007","journal-title":"Mov. Disord."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/MNM.0b013e32833b7ea4","article-title":"Interobserver reproducibility of the interpretation of I-123 FP-CIT single-photon emission computed tomography","volume":"31","author":"Tondeur","year":"2010","journal-title":"Nucl. Med. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12149-011-0564-1","article-title":"Interobserver variability, and visual and quantitative parameters of (123)I-FP-CIT SPECT (DaTSCAN) studies","volume":"26","author":"Papathanasiou","year":"2012","journal-title":"Ann. Nucl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Wakasugi, N., Takano, H., Abe, M., Sawamoto, N., Murai, T., Mizuno, T., Matsuoka, T., Yamakuni, R., Yabe, H., and Matsuda, H. (2024). Harmonizing multisite data with the ComBat method for enhanced Parkinson\u2019s disease diagnosis via DAT-SPECT. Front. Neurol., 15.","DOI":"10.3389\/fneur.2024.1306546"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s00259-007-0621-0","article-title":"Dopamine transporter imaging with [123I]FP-CIT SPECT: Potential effects of drugs","volume":"35","author":"Booij","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41598-021-04078-x","article-title":"Influence of brain atrophy using semiquantitative analysis in [123I]FP-CIT single-photon emission computed tomography by a Monte Carlo simulation study","volume":"12","author":"Nosaka","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.nima.2006.10.236","article-title":"Accuracy of partial volume effect correction in clinical molecular imaging of dopamine transporter using SPECT","volume":"571","author":"Soret","year":"2007","journal-title":"Nucl. Instrum. Methods Phys. Res. A"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.2967\/jnumed.110.078337","article-title":"Serotonin transporters in dopamine transporter imaging: A head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I","volume":"51","author":"Ziebell","year":"2010","journal-title":"J. Nucl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Lorio, S., Sambataro, F., Bertolino, A., Draganski, B., and Dukart, J. (2019). The combination of DAT-SPECT, structural and diffusion MRI predicts clinical progression in Parkinson\u2019s disease. Front. Aging Neurosci., 11.","DOI":"10.3389\/fnagi.2019.00057"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s10278-025-01583-7","article-title":"Prediction of motor symptom progression of Parkinson\u2019s disease through multimodal imaging-based machine learning","volume":"39","author":"Dai","year":"2026","journal-title":"J. Imaging Inform. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmp.2020.05.010","article-title":"MRI-guided voxel-based automatic semi-quantification of dopamine transporter imaging","volume":"75","author":"Trnka","year":"2020","journal-title":"Phys. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"107898","DOI":"10.1016\/j.parkreldis.2025.107898","article-title":"Comparative diagnostic efficacy of neuromelanin MRI vs. dopamine transporter (DAT) imaging in Parkinson\u2019s disease: A systematic review","volume":"137","author":"Burade","year":"2025","journal-title":"Park. Relat. Disord."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"112289","DOI":"10.1016\/j.pscychresns.2026.112289","article-title":"Combining neuromelanin-sensitive MRI and quantitative susceptibility mapping for enhanced diagnosis and differentiation of Parkinson\u2019s disease: A systematic review","volume":"363","author":"Nikparast","year":"2026","journal-title":"Psychiatry Res. Neuroimaging"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13550-022-00930-x","article-title":"[18F]FE-PE2I PET is a feasible alternative to [123I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism","volume":"12","author":"Marner","year":"2022","journal-title":"EJNMMI Res."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Ribeiro, M.-J., Vercouillie, J., Arlicot, N., Tauber, C., Gissot, V., Mondon, K., Barantin, L., Cottier, J.-P., Maia, S., and Deloye, J.-B. (2020). Usefulness of PET with [18F]LBT-999 for the evaluation of presynaptic dopaminergic neuronal loss in a clinical environment. Front. Neurol., 11.","DOI":"10.3389\/fneur.2020.00754"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1002\/mds.30255","article-title":"Normal [18F]FE-PE2I PET in patients with persistent diagnostic uncertainty after abnormal [123I]FP-CIT SPECT","volume":"40","author":"Dhadamus","year":"2025","journal-title":"Mov. Disord."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"103290","DOI":"10.1016\/j.arr.2026.103290","article-title":"Mitochondrial homeostasis dysregulation: Potential mechanisms of Alzheimer\u2019s disease mediated by TDP-43","volume":"121","author":"Huang","year":"2026","journal-title":"Ageing Res. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e70115","DOI":"10.1002\/imo2.70115","article-title":"Strategies and mechanisms of precision genome engineering: From gene editing to genome writing","volume":"3","author":"Huang","year":"2026","journal-title":"iMetaOmics"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"106101","DOI":"10.1016\/j.parkreldis.2024.106101","article-title":"Brain-first vs. body-first Parkinson\u2019s disease: An update on recent evidence","volume":"122","author":"Horsager","year":"2024","journal-title":"Park. Relat. Disord."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41531-024-00685-3","article-title":"Investigating the aspect of asymmetry in brain-first versus body-first Parkinson\u2019s disease","volume":"10","author":"Carli","year":"2024","journal-title":"npj Park. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41531-025-01164-z","article-title":"Discriminating between proposed brain-first and body-first Parkinson\u2019s disease using conventional and radiomics-enhanced dopamine transporter SPECT image analysis","volume":"11","author":"Palermo","year":"2025","journal-title":"npj Park. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/jamaneurol.2017.0985","article-title":"Conversion to Parkinson disease in the PARS hyposmic and dopamine transporter-deficit prodromal cohort","volume":"74","author":"Jennings","year":"2017","journal-title":"JAMA Neurol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/acn3.51269","article-title":"Dopamine transporter imaging predicts clinically-defined \u03b1-synucleinopathy in REM sleep behavior disorder","volume":"8","author":"Chahine","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Pitton Rissardo, J., and Caprara, A.L.F. (2023). Cardiac 123I-metaiodobenzylguanidine (MIBG) scintigraphy in Parkinson\u2019s disease: A comprehensive review. Brain Sci., 13.","DOI":"10.3390\/brainsci13101471"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14802\/jmd.25137","article-title":"Cardiac 123I-meta-iodobenzylguanidine imaging as a biomarker for body-first Parkinson\u2019s disease: Linking peripheral \u03b1-synuclein to clinical subtyping","volume":"19","author":"Ryu","year":"2026","journal-title":"J. Mov. Disord."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1093\/brain\/awaa238","article-title":"Brain-first versus body-first Parkinson\u2019s disease: A multimodal imaging case-control study","volume":"143","author":"Horsager","year":"2020","journal-title":"Brain"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1212\/WNL.0000000000003633","article-title":"Decreased intestinal acetylcholinesterase in early Parkinson disease: An 11C-donepezil PET study","volume":"88","author":"Fedorova","year":"2017","journal-title":"Neurology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1212\/WNL.0000000000000424","article-title":"Longitudinal follow-up of SWEDD subjects in the PRECEPT study","volume":"82","author":"Marek","year":"2014","journal-title":"Neurology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/acn3.644","article-title":"The Parkinson\u2019s progression markers initiative (PPMI)\u2014Establishing a PD biomarker cohort","volume":"5","author":"Marek","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/mds.26018","article-title":"Patients with scans without evidence of dopaminergic deficit: A long-term follow-up study","volume":"29","author":"Batla","year":"2014","journal-title":"Mov. Disord."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/mds.23019","article-title":"Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson\u2019s disease: A clinical and electrophysiological study","volume":"25","author":"Schwingenschuh","year":"2010","journal-title":"Mov. Disord."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/mds.26204","article-title":"Nonmotor symptoms in subjects without evidence of dopaminergic deficits","volume":"30","author":"Sprenger","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/jnnp-2014-310256","article-title":"What do patients with scans without evidence of dopaminergic deficit (SWEDD) have? New evidence and continuing controversies","volume":"87","author":"Erro","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/nrneurol.2015.86","article-title":"Dopa-responsive dystonia\u2014Clinical and genetic heterogeneity","volume":"11","author":"Wijemanne","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/RLU.0000000000001696","article-title":"Utility of follow-up dopamine transporter SPECT with 123I-FP-CIT in the diagnostic workup of patients with clinically uncertain parkinsonian syndrome","volume":"42","author":"Apostolova","year":"2017","journal-title":"Clin. Nucl. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.nicl.2017.09.010","article-title":"Refining diagnosis of Parkinson\u2019s disease with deep learning-based interpretation of dopamine transporter imaging","volume":"16","author":"Choi","year":"2017","journal-title":"Neuroimage Clin."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/MNM.0000000000000890","article-title":"Artificial intelligence in the diagnosis of Parkinson\u2019s disease from ioflupane-123 single-photon emission computed tomography dopamine transporter scans using transfer learning","volume":"39","author":"Kim","year":"2018","journal-title":"Nucl. Med. Commun."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"104041","DOI":"10.1016\/j.compbiomed.2020.104041","article-title":"An explainable machine learning model for early detection of Parkinson\u2019s disease using LIME on DaTSCAN imagery","volume":"126","author":"Magesh","year":"2020","journal-title":"Comput. Biol. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijmedinf.2016.03.001","article-title":"High-accuracy detection of early Parkinson\u2019s disease through multimodal features and machine learning","volume":"90","author":"Prashanth","year":"2016","journal-title":"Int. J. Med. Inform."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2967\/jnumed.124.267570","article-title":"Unrealistic data augmentation improves the robustness of deep learning-based classification of dopamine transporter SPECT against variability between sites and between cameras","volume":"65","author":"Buddenkotte","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s00259-024-06961-x","article-title":"Dopaminergic PET to SPECT domain adaptation: A cycle GAN translation approach","volume":"52","author":"Lopes","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Sung, C., Oh, J.S., Chae, S.Y., Lee, D.Y., Oh, M., Lee, S.J., Oh, S.J., Jo, S., Chung, S.J., and Kim, J.S. (2026). Development of AI-based dopamine transporter (DAT) image generation technique using early phase [18F]-FP-CIT PET imaging. PLoS ONE, 21.","DOI":"10.1371\/journal.pone.0349375"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/9\/1545\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:18:54Z","timestamp":1789553934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/9\/1545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":75,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["life16091545"],"URL":"https:\/\/doi.org\/10.3390\/life16091545","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]}}}